D-penicillamine reduces serum oxidative stress in Alzheimer's disease patients

European Journal of Clinical Investigation

Volumn 32, Issue 1, 2002, Pages 51-59

  Squitti, Rosanna ^a,c   Rossini, P M ^a,c,d   Cassetta, E ^a   Moffa, F ^a   Pasqualetti, P ^a   Cortesi, M ^a   Colloca, A ^a   Rossi, L ^b   Finazzi Agro A ^b  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Alzheimer's disease; Chelating agent; Copper; D penicillamine; Iron; Oxidative stress

Indexed keywords

ANTIOXIDANT; CHELATING AGENT; COPPER; PENICILLAMINE; PEROXIDE;

ADULT; AGED; ALZHEIMER DISEASE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPPER BLOOD LEVEL; CORRELATION ANALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; MALE; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHELATING AGENTS; COPPER; DISEASE PROGRESSION; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; OXIDATIVE STRESS; PENICILLAMINE; PILOT PROJECTS; RETROSPECTIVE STUDIES;

EID: 0037003044     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00933.x     Document Type: Conference Paper

References (59)

1. Roche E, Romero-Alvira D. Oxidative stress in some dementia types [Review]. Med Hypoth 1993;40:342-50.
2. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990;55:342-5.
3. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Rad Biol Med 1999;27:544-53.
4. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzymes activity in the brain in Alzheimer's disease. Neurology 1995;45:1594-601.
5. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med 1997;23:134-47.
6. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52.
7. Smith MA, Perry G. Free radical damage, iron, and Alzheimer's disease. J Neurol Sci 1995;134 (Suppl.):92-4.
8. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866-8.
9. Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper (II) to copper (I). Science 1996;271:1406-9.
10. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
11. Frisoni GB, Govoni S, Geroldi C, Bianchetti A, Calabresi L, Franceschini G, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995;37:596-604.
12. Frisoni GB, Geroldi C, Bianchetti A, Binetti G, Trabucchi M. The gain of Apolipoprotein E genotyping to separate patients with Alzheimer's disease from normal individuals: relevance to community studies. Dementia 1996;7:336-42.
13. Gonzalez C, Martin T, Cacho J, Brenas MT, Arroyo T, Garcia-Berrocal B, et al. Serum zinc, copper, insulin, and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 1999;29:637-42.
14. Ihara Y, Hayabara T, Sasaki K, Fujisawa Y, Kawada R, Yamamoto T, et al. Free radicals and superoxide dismutase in blood of patients with Alzheimer's disease and vascular dementia. J Neurol Sci 1997;153:76-81.
15. Curti D, Rognoni F, Gasparini L, Cattaneo A, Paolillo M, Racchi M, et al. Oxidative metabolism in cultered fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neurosci Lett 1997;236:13-16.
16. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatr 1998;13:840-5.
17. Famulari AL, Marschoff ER, Llesuy SF, Kohan S, Serra JA, Dominguez RO, et al. The antioxidant blood profile in Alzheimer's disease and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls. J Neurol Sci 1996;141:69-78.
18. White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, et al. The Alzheimer's disease amyloid precursors protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 1999;19:9170-9.
19. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000;74:270-9.
20. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, et al. Cu (II) potentiation of Alzheimer Abeta neurotoxicity. Correlation with cell-free hydrogenperoxide production and metal reduction. J Biol Chem 1999;274:37111-16.
21. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL, et al. Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol 1997;54:533-9.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinic diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
23. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
24. Otomo S, Sasajima M, Ohzeki M, Tanaka I. Effects of D-penicillamine on vitamin B6 and metal ions in rats. Nippon Yakurigaku Zasshi 1980;76:1-13.
25. Hixson JE, Vernier DT. Restriction isotyping of human APOE by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.
26. Alberti A, Bolognini L, Macciantelli D, Carratelli M. The radical cation of N,N-Diethyl-para-phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed 2000;26:253-67.
27. Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L, et al. A simple test to monitor oxidative stress. Int Angiol 1999;18:127-30.
28. Kusmic C, Petersen C, Picano E, Busceti C, Parenti G, Laghi Pasini F, et al. Antioxidant effect of oral dipyridamole during cerebral hypoperfusion with human carotid endarterectomy. J Cardiovasc Pharm 2000;36:141-5.
29. Buonocore G, Perrone S, Longini M, Terzuoli L, Brracci R. Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res 2000;47:221-4.
30. Trotti R, Carratelli M, Barbieri M, Micieli G, Bosone D, Rondanelli M, et al. Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica 2001;86:85-91.
31. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Meth Enzymol 1994;234:279-475.
32. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407-12.
33. Abe A, Yamashita S, Noma A. Sensitive, direct colorimetric assay for copper in serum. Clin Chem 1989;35:552-4.
34. Siedel J, Wahlefeld AW, Ziegenhorn J. A new iron ferrozine reagent without deproteinization. Clin Chem 1984;30:975 (AACC-Meeting (Abstract)).
35. Wick M, Pinggera W, Lehmann P, eds. Iron Metabolism Diagnosis and Therapy of Anemias 3rd edn. Vienna, New York: Springer-Verlag; 1996.
36. Lievens M, de Borque Larrea L, Rus A. Determination of transferrin without sample predilution by a turbidimetric assay on Boehringer Mannheim/Hitachi analysis systems. Lab Med 1994;18:83-90.
37. Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardisation of the Mental Deterioration Battery. Eur Neurol 1996;36:378-84.
38. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998;46:210-15.
39. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. Psychiatr Res 1982-83;17:37-49.
40. Gottifries CG, Brane G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982;1:311-30.
41. Wright GD, Wilson C, Bell AL. D-penicillamine induced polymyositis causing complete heart block. Clin Rheumatol 1994;13:80-2.
42. Atwood CS, Huang X, Moir RD, Tanzi RE, Bush AI. The role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. In: Sigel H, editors. Interrelations Between Free Radicals and Metal Ions in Life Processes. New York: Marcel Dekker; 1999 pp. 309-64.
43. Sayre LM, Perry G, Smith MA. Redox metals and neurode-generative disease. Curr Opin Chem Biol 1999;3:220-5.
44. Haliwell B, Gutteridge J. Oxygen is poisonous - an introduction to oxygen toxicity and free radicals. In: Haliwell B, Gutteridge J, editors. Free Radicals in Biology and Medice. Oxford: Clarendon Press; 1989 pp. 1-21.
45. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, et al. Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of the Aβ by zinc. J Biol Chem 2000;275:19439-42.
46. De Leo ME, Borrello S, Passantino M, Palazzotti B, Mordente A, Daniele A, et al. Oxidative stress overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci Lett 1998;250:173-6.
47. Repetto MG, Reides CG, Evelson P, de Kohan S, Lustig ES, Llesuy SF. Peripheral markers of oxidative stress in probable Alzheimer patients. Eur J Clin Inves 1999;29:643-9.
48. Perkins AJ, Hendrie HC, Callahan CM, Gao S, Unverzagt FW, Xu Y, et al. Association of antioxidants with memory in multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. AM J Epidemiol 1999;150:37-44.
49. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 1998;19:339-45.
50. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989;35:275-582.
51. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Bill E, Pipkorn R, et al. Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. Biochemistry 1998;37:7224-30.
52. Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li QX, McLean CA, et al. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's diseases. J Struct Biol 2000;130:209-16.
53. Moir RD, Atwood CS, Huang X, Tanzi RE, Bush AI. Mounting evidence for the involvement of zinc and copper in Alzheimer's disease. Eur J Clin Invest 1999;29:569-70.
54. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76.
55. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304-8.
56. Scheinberg IH, Sternlieb I. Wilson disease. In: Scheinberg IH, Sternlieb I, editors. Philadelphia: W.B. Saunders; 1984 pp. 25-37.
57. Kato N, Nakamura M, Uchiyama T. 1H NMR studies of the reactions of copper (I) and copper (II) with D-penicillamine and glutathione. J Inorg Biochem 1999;75:117-21.
58. Calabrese V, Calderone A, Ragusa N, Rizza V. Effects of metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats. Drugs Exp Clin Res year? ;1996:17-24.
59. Brewer GJ. Practical recommendations and new therapies of Wilson's disease. Drugs 1995;50:240-9.